GlobalData on MSN21h
Takeda broadens its deal with BridGene for up to $770mBridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology. Takeda will pay ...
GlobalData on MSN1d
EMA approves Takeda’s Takhzyro pre-filled pen option for HAEThe current approval of Takeda’s Takhzyro pre-filled pen is an addition to the existing 150 mg and 300 mg pre-filled syringes ...
BridGene strikes another partnership with Takeda as the latter company continues its dealmaking streak, following high-ticket ...
Takeda has returned to BridGene Biosciences for another small-molecule collaboration—this time focused on immunology as well ...
Privately-held BridGene Biosciences has announced a strategic collaboration and licensing agreement with Japan’s Takeda. The ...
Cash position strengthened: In February 2025, Keros received a $200.0 million upfront payment pursuant to the exclusive ...
BridGene Biosciences Inc. has entered a strategic collaboration and licensing agreement with Takeda through which it will use ...
Takeda (TAK) announced that the EMA has approved an additional two mL pre-filled pen option for Takhzyro for subcutaneous administration in ...
Zurich: Takeda has announced that the European Medicines Agency (EMA) has given approval for an additional 2 mL pre-filled ...
In a phase 2 trial, lusvertikimab significantly improves clinical and endoscopic outcomes in patients with moderate to severe ...
Corundum Systems Biology, an investment firm supporting early-stage companies developing biomedical solutions, hired operating partner Henry Haiser, PhD from Takeda and Rotem Gura-Sadovsky, PhD as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback